pseudotype – an open-access journal of pseudotyped & chimeric viruses – will consider and publish peer-reviewed studies that make significant advances in the field of viral pseudotyping in the following general areas of hybrid/recombinant viruses:
- Pseudotypes as serological antigens
- Pseudotypes as vaccines
- Pseudotypes as diagnostics
- Comparative serology involving pseudotype assays
- New vector systems for pseudotyping
- New/improved/refined assays and platforms for antiviral screening and drug resistance testing
The journal has a strong belief the impact both positive and negative data can have on scientific research so actively encourages the submission of both.
The following categories of manuscripts will be considered for publication:
- Full research articles
- Short communications
- News (including R&D) and Editorials linked to the above
- New methods and technologies
- Research letters
- Meeting reports
Route to publication
The journal aims publish accepted manuscripts within 10-12 weeks of manuscript submission. Each manuscript will be assigned an editor who oversees the review process, undertaken by at least 2 experts in the field. Following acceptance, manuscripts will be made available online in their final form within 2-3 weeks. The journal will be primarily published online but on sufficient demand for printed version journal hard copies may also be provided to individuals and institutions.
Submission of a manuscript to the Journal implies that no part of the manuscript has been previously published in any language in a permanent archive, or the whole manuscript or any part of the manuscript is being considered for publication by another journal, or it violates anyone’s copyrights or any other rights. Reproduction of tables and figures from previously published articles must accompany written permission from the copyright holder(s) and should be provided at the time of manuscript submission. Authors must also submit any closely-related manuscripts in press or submitted for publication to another journal. The corresponding/senior author is responsible for obtaining permission of manuscript submission from all co-authors, and for ensuring that all co-authors are in complete agreement with the contents of the manuscript and its authorship. It is also assumed that authors have complied with all ethical and privacy guidelines and/or legislation concerning the submitted work – particularly related to the use of human or animal subjects and cloning research. If the work is multidisciplinary, all collaborators must ensure that they have appropriate measures in place to check the accuracy of their part of the data. The corresponding/senior author has the overall responsibility for the accuracy of the data presented in the manuscript. However, each author also has direct responsibility for the contents of the paper. Editors have the right to accept or reject an article solely on whether it fits the scope and guidelines of the journal.
Submission of a manuscript to the journal implies that the author(s) fully agree to and understand the terms and conditions, and accept the policies of the journal described under the ‘Information for Authors’ at the time of manuscript submission.
Publication in pseudotype implies that authors are prepared to provide, at reasonable costs, on request any reported strains, cell line, clones, molecules, etc., developed in their laboratories that are not commercially available, to colleagues in other academic, medical and non-profit research institutions.